Lacosamide

Drug Profile

Lacosamide

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Phase II/III Epilepsy
  • Preclinical Pain
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 28 Jul 2017 UCB Biopharma completes phase I trial in Epilepsy (In volunteers) in China (IV) (NCT03204474)
  • 21 Jul 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval for Partial-onset seizures (In children) in European Union
  • 19 Jul 2017 Preregistration for Partial epilepsies (In children) in European Union (PO) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top